4LPB
| Crystal structure of a topoisomerase ATPase inhibitor | Descriptor: | 1-ethyl-3-{5'-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-4-[4-(trifluoromethyl)-1,3-thiazol-2-yl]-3,3'-bipyridin-6-yl}urea, Topoisomerase IV subunit B | Authors: | Boriack-Sjodin, A. | Deposit date: | 2013-07-15 | Release date: | 2013-10-30 | Last modified: | 2024-02-28 | Method: | X-RAY DIFFRACTION (1.75 Å) | Cite: | Fragment-to-Hit-to-Lead Discovery of a Novel Pyridylurea Scaffold of ATP Competitive Dual Targeting Type II Topoisomerase Inhibiting Antibacterial Agents. J.Med.Chem., 56, 2013
|
|
4HLC
| Sulfonylpiperidines as Novel, Antibacterial Inhibitors of Gram-Positive Thymidylate Kinase (TMK): Compound 5 | Descriptor: | 4-{[(3S)-3-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl]sulfonyl}-2-(3-methylphenoxy)benzoic acid, Thymidylate kinase | Authors: | Boriack-Sjodin, A, Olivier, N. | Deposit date: | 2012-10-16 | Release date: | 2012-10-31 | Last modified: | 2024-04-03 | Method: | X-RAY DIFFRACTION (1.55 Å) | Cite: | Sulfonylpiperidines as novel, antibacterial inhibitors of Gram-positive thymidylate kinase (TMK). Bioorg.Med.Chem.Lett., 23, 2013
|
|
1KD7
| Crystal structure of an extracellular domain fragment of human BAFF | Descriptor: | TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13B | Authors: | Karpusas, M, Cachero, T.G, Qian, F, Boriack-Sjodin, A, Mullen, C, Strauch, K, Hsu, Y.-M, Kalled, S.L. | Deposit date: | 2001-11-12 | Release date: | 2002-11-12 | Last modified: | 2017-02-01 | Method: | X-RAY DIFFRACTION (2.8 Å) | Cite: | Crystal Structure of Extracellular Human BAFF, a TNF Family Member that Stimulates B Lymphocytes J.Mol.Biol., 315, 2002
|
|
4KY1
| humanized HP1/2 Fab | Descriptor: | IMMUNOGLOBULIN IGG1 FAB, HEAVY CHAIN, LIGHT CHAIN | Authors: | Arndt, J.W, Hanf, K.J.M, Lugovskoy, A, Chen, L.L, Jarpe, M, Boriack-Sjodin, A, Li, Y, van Vlijmen, H, Pepinsky, B, Taylor, F, Silvian, L, Taveras, A. | Deposit date: | 2013-05-28 | Release date: | 2013-07-24 | Last modified: | 2023-09-20 | Method: | X-RAY DIFFRACTION (2.97 Å) | Cite: | Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework. METHODS (SAN DIEGO), 65, 2014
|
|